🚨 BREAKING: Europe's medicines watchdog has recommended Novo Nordisk's #semaglutide pill for approval, which would make it the first oral weight-loss drug on the continent. Get the full details: www.emjreviews.com/emj-gold/new... #Obesity #Pharma #GLP1

The use of AI in medical imaging is on the rise – the market could grow by 30% over the next five years – but what's the main driver behind the uptick? Find out: www.emjreviews.com/emj-gold/new... #ArtificialIntelligence #HealthTech #MedicalImaging #Radiology

“The science is moving faster than the regulatory system around it.” To celebrate #WorldClinicalTrialsDay, the team spoke to Muriel O’Byrne, Regeneron, about the opportunities and challenges shaping the future of clinical trials today. Read now: www.emjreviews.com/emj-gold/art...

A new study by Prof Majid Ezzati of @imperialcollegeldn.bsky.social has examined global obesity rates, uncovering a black mark on the otherwise rosy picture of improved outcomes. Read the story: www.emjreviews.com/emj-gold/new...

Following the latest #Ebolavirus outbreak in the Democratic Republic of Congo, attention is turning to antiviral candidates such as #NanoViricides’ NV-387 – a stable oral antiviral in that may also be available as a gummy. Learn more: www.emjreviews.com/emj-gold/new...

Has the UK learned from past mistakes in pandemic policy? The nation has imported the experimental antiviral drug favipiravir as a precaution against any further cases of the deadly #Andeshantavirus. Read now: www.emjreviews.com/emj-gold/new...

After daraxonrasib's phase 3 trial results were released, there has reportedly been “a deluge of patient requests” for the therapy. Learn more: hubs.ly/Q04gCHKC0 #PancreaticCancer #daraxonrasib

Couldn't make it to #WIREDHealth2026? We've got the pharma highlights. The team was there to find out how healthcare leaders, NHS figures and tech executives think AI, data and new technologies could reshape medicine. Read the roundup: www.emjreviews.com/emj-gold/art...

Update: GSK has partnered with Sino Biopharmaceutical subsidiary CTTQ to commercialise investigational hepatitis B therapy bepirovirsen in China. Read more: www.emjreviews.com/emj-gold/new... #HepatitisB #ChinaHealthcare

April in pharma, explained 👇 In our latest news roundup, explore: - A major month for the obesity market - The impact of war on clinical trials - The rise of tech giants in AI-driven R&D. Read it now: www.emjreviews.com/emj-gold/new...

Major M&A move: #Angelini Pharma is buying #Catalyst Pharmaceuticals, Inc. for $4.1bn in its biggest deal to date and its first significant move into the US market. Read the story: hubs.la/Q04fPHZP0 #neurology #brainhealth

#Novartis has been selected as an official partner of the 2029 #SpecialOlympics World Winter Games, which bring together athletes with cognitive disabilities to compete in elite winter sports such as skiing, figure skating and snowboarding. Discover more: www.emjreviews.com/emj-gold/new...

The remote prescription of the abortion pill #mifepristone is under threat from a lawsuit by Louisiana, but the Supreme Court has blocked the ruling for now. Discover the full story: www.emjreviews.com/emj-gold/new...

LEO Pharma has acquired Replay, a herpes simplex virus (HSV) gene therapy platform, for $50m. This will expand the company’s presence in rare dermatology. Learn more: hubs.ly/Q04f7NZs0 #dermatology #genetherapy #LEOPharma

The results are in 📣 It's time to see what held firm and what trends took shape. How did HCPs consume medical content in 2025? Find out now: www.emjreviews.com/emj-gold/inf... #pharmamarketing #medicalaffairs

Is the UK-US pricing deal working? New investments from #AstraZeneca and #BoehringerIngelheim suggest it is. The companies have pledged almost half a billion pounds to new sites in the country, indicating a thawing of frosty relations between the UK and pharma. www.emjreviews.com/emj-gold/new...

More exciting news: Well done to the #EMJPodcast for being shortlisted for the Audio Content of the Year at the 2026 Professional Publishers Association (PPA) Awards. Winners will be revealed on Wednesday 17 June 2026. Learn more: www.emjreviews.com/emj-gold/new...

Congratulations to @emjreviews.com for getting shortlisted in the Healthcare & Pharma category for The Drum Awards 2026 🏆 The awards recognise work that demonstrates effectiveness and innovation in healthcare communications. Read more: hubs.la/Q04dyFYl0

“Sometimes I don’t understand why people would want to do something else.” Andrew Menzies-Gow, VP, #AstraZeneca, loves his job. In this interview, he talks diagnosis gaps, shifting COPD thinking and fixing care. Read now: www.emjreviews.com/emj-gold/art... #Respiratory #COPD #asthma

Bird flu is on the rise. As cases in poultry climb, Moderna is gaining with momentum with its vaccine, launching a phase 3 trial in its race to develop a solution against the fast-spreading virus. Discover more: www.emjreviews.com/emj-gold/new... #birdflu #vaccines #Moderna

A federal court has come down hard on Robert F. Kennedy Jr.’s CDC advisory panel appointments – blocking them over concerns around expertise and process, and freezing key vaccine recommendations in the process. Learn more about the case: www.emjreviews.com/emj-gold/new...

Is Eli Lilly hedging its bets outside of the obesity market? The company plans to buy Kelonia Therapeutics for up to $7bn, gaining access to an experimental multiple myeloma therapy that reprogrammes patients’ immune cells inside the body. Learn more: www.emjreviews.com/emj-gold/new...

Calling all those in cancer care. In this new column, Dr Henar Hevia, J&J Innovative Medicine, explores how real-world evidence and better decision-making can improve outcomes, personalise treatment and close the gap between innovation and care. Read now: hubs.la/Q04cv8dL0

More from #WIREDHealth: Kathleen Fisher, CEO, ARIA, shared a story about failure. A synthetic blood programme didn’t work as intended. But the same technology showed potential elsewhere. It eventually led to Moderna’s mRNA platform. Sign up for more: www.emjreviews.com/mailing-list/

The team are at #WIREDHealth to capture the key insights for pharma. Top moment so far: Lord Vallance calls on UK funds to invest in life sciences, noting only Canadian funds, and pensioners, are currently reaping the rewards. Sign up for full round up: www.emjreviews.com/mailing-list/

Amazon Web Services has launched a new artificial intelligence platform for drug discovery, which, crucially, researchers can use without writing code for the first time. Early adopters include @mskcancercenter.bsky.social. Learn more: www.emjreviews.com/emj-gold/new... #AIinHealthcare

Update: Novo Nordisk join forces with with OpenAI. “This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare," said President and CEO Mike Doustdar. Read more: www.emjreviews.com/emj-gold/new...

Is CMS reshaping cannabinoid access policy through the back door? A new federal pilot allows Medicare organisations to discuss and furnish hemp-derived CBD products - without FDA approval and without going through standard regulatory process. 🔗: hubs.la/Q04bp4X70

Novo Nordisk has launched a 7.2 mg semaglutide injection in the US, nearly three times the previous highest available dose. Learn more: www.emjreviews.com/emj-gold/new...

Cardiovascular disease costs the world $680bn a year. A new OHE report suggests up to $480bn of that could be avoided. The key? Early detection and management of moderately elevated LDL-C at scale. Read more: www.emjreviews.com/emj-gold/new...

Great science means nothing if patients can't trust, understand or use it. VML Health's Health Futures 2026 report warns that rising misinformation is eroding patient confidence faster than innovation can rebuild it. Read more: www.emjreviews.com/emj-gold/new... #WorldHealthDay

Big news in obesity care: Eli Lilly’s once-daily oral GLP-1, orforglipron, has received FDA approval. In clinical trials, patients achieved ~12% weight loss at the highest dose, alongside improvements in key cardiovascular risk factors. Read more: www.emjreviews.com/emj-gold/new...

Month in pharma: March 2026, explained 👇 From Takeda's restructure to fuel its late-stage pipeline, to space-based drug manufacturing gaining traction in the UK, March showed the industry is never a boring place to be. Discover the full round up: www.emjreviews.com/emj-gold/new...

Is FDA scrutiny of biologics marketing increasing? The CBER has ended a period of relative dormancy with a rare quartet of untitled letters to Iovance, BMS, Novartis and Gilead’s Kite Pharma. Learn more: www.emjreviews.com/emj-gold/new...

Lilly and Insilico strike $2.75bn AI R&D alliance EliLilly and Company has entered a major strategic collaboration with Insilico Medicine, marking a high-stakes expansion of generative AI in its pipeline Learn more: www.emjreviews.com/emj-gold/new...

Endometriosis treatment has long meant hormones, side effects and trade-offs. What if the next wave targets inflammation instead? A new phase 2 trial from Gesynta Pharma is underway, investigating a non-hormonal treatment for the condition. Read now: www.emjreviews.com/emj-gold/new...

Takeda is betting big on a leaner, tech-driven future. With a board-approved strategy aimed at delivering $1.25bn in savings by 2028, the Japanese pharma giant is preparing for a significant company restructure. Explore more: www.emjreviews.com/emj-gold/new...

What does the Middle East conflict mean for pharma supply chains? The evolving situation in the Gulf isn’t just a supply chain disruption, it may threaten the integrity of ultra-cold chain biologics and the affordability of generics. Read now: www.emjreviews.com/emj-gold/art...

Could Georgia be the next major hub for US life sciences? UCB is expanding its US manufacturing operations with a new $2bn biologics hub in Georgia and will support the production of primarily neurology and immunology therapies. Learn more: www.emjreviews.com/emj-gold/new...

Can AbbVie help strike out cancer on a global scale? ⚾️ AbbVie is stepping up to the plate as Major League Baseball’s (MLB) first-ever official pharmaceutical partner, starting in the 2026 season. Learn more: www.emjreviews.com/emj-gold/new... #MLB #Strikeoutcancer #AbbVie

The #ABPI is urging the UK to unlock #NHS data to fix a broken trial recruitment pipeline. It says smarter use of anonymised records could speed up commercial studies, cut waste and keep the UK in the global race for pharma investment. Learn more: www.emjreviews.com/emj-gold/new...

The end of the animal testing default? The FDA has released a roadmap for validating New Approach Methodologies (NAMs) to build safer, more effective therapies with higher regulatory confidence. Read more on the shift to NAMs: www.emjreviews.com/emj-gold/new...

Roche is scaling up its 'AI factories' with the help of NVIDIA GPUs. By using thousands of specially trained models, Roche aims to reduce the time taken to detect and design high-potential clinical candidates from years to just months. Read more: www.emjreviews.com/emj-gold/new...

Can vaccines withstand lower storage temperatures? A new trial put the cold chain to the test with a tetanus and diphtheria vaccine, and the results were promising. Learn more: www.emjreviews.com/emj-gold/new...

Is basic healthcare becoming unaffordable for the average American? The latest West Health–Gallup Healthcare Affordability Index revealed a troubling trend: perceptions of affordability are at their lowest since the survey began. Find out more: www.emjreviews.com/emj-gold/new...

#BioNTech enters a new phase of clinical evolution as co-founders Prof Ugur Sahin and Prof Özlem Türeci announce their planned exit to launch an independent mRNA venture. Read the full story: www.emjreviews.com/emj-gold/new...

Think you're a medical affairs whizz? Test your knowledge with our brand new quiz! From the origins of the medical affairs to the modern challenges of omnichannel engagement, see how well you know pharma’s ever-evolving function. Take the quiz to see how you do: www.emjreviews.com/en-us/amj/em...

The UK is taking the pharmaceutical supply chain into orbit. 🚀 A new regulatory roadmap from the UK Space Agency, MHRA and CAA clears the flight path for in-orbit drug manufacturing. The UK is officially open for extraterrestrial R&D. Read more: www.emjreviews.com/emj-gold/new...

Can a Parisian biotech startup revolutionise Servier’s antibody pipeline? Servier has announced a strategic collaboration with kyron.bio to develop next-generation treatments for oncology and autoimmune diseases. Learn more: www.emjreviews.com/emj-gold/new...

Is South Korea the new destination for drug development? Roche thinks so. The healthcare giant has pledged $481m to help the nation become a strategic hub for global clinical trials and health innovation. Learn more: www.emjreviews.com/emj-gold/new...